Sign In
Buy CMMB
$1.72
-0.0200 (-1.15%)
At Close: Jun 03, 2026
Chemomab Therapeutics to Report Second Quarter 2024 Financial Results and Provide a Business Update
07:00am, Monday, 12'th Aug 2024
TEL AVIV, Israel, Aug. 12, 2024 (GLOBE NEWSWIRE) -- Chemomab Therapeutics Ltd. (Nasdaq: CMMB) (“Chemomab” or the “Company”), a clinical stage biotechnology company developing innovative therap
Chemomab Therapeutics Announces Closing of $10 Million Private Placement
09:00am, Tuesday, 30'th Jul 2024
Chemomab closed a $10 million PIPE financing that included new and existing top tier investors and extends the cash runway through the beginning of 2026
Chemomab Therapeutics Regains Compliance With Nasdaq Minimum Bid Price Requirement
07:00am, Friday, 26'th Jul 2024
TEL AVIV, Israel, July 26, 2024 (GLOBE NEWSWIRE) -- Chemomab Therapeutics Ltd. (Nasdaq: CMMB) (Chemomab) a clinical stage biotechnology company developing innovative therapeutics for fibro-inflammator
Chemomab Therapeutics Announces $10 Million Private Placement
07:38am, Thursday, 25'th Jul 2024
Chemomab announced a $10 million PIPE that enables the company to extend its cash runway until early 2026, well past 2 upcoming milestones in early 2025.
Chemomab reported positive topline results from Ph 2 trial assessing CM-101 in PSC. Achieved safety endpoint and improved wide range of secondary endpoints
Chemomab Therapeutics (CMMB) Upgraded to Buy: Here's What You Should Know
01:01pm, Thursday, 27'th Jun 2024
Chemomab Therapeutics (CMMB) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
—Ex Vivo Studies Using Clinical Samples from Patients with Liver Fibrosis Reinforce the Anti-Fibrotic Activity of CM-101 by Showing the Drug's Direct Interference with Liver Fibroblast Activation—
Chemomab Therapeutics to Participate in Upcoming Scientific Conferences
07:00am, Friday, 17'th May 2024
TEL AVIV, Israel, May 17, 2024 (GLOBE NEWSWIRE) -- Chemomab Therapeutics Ltd. (Nasdaq: CMMB) (Chemomab), a clinical stage biotechnology company developing innovative therapeutics for fibro-inflammator
Chemomab Therapeutics Ltd. Sponsored ADR (CMMB) Now Trades Above Golden Cross: Time to Buy?
10:56am, Friday, 10'th May 2024
After reaching an important support level, Chemomab Therapeutics Ltd. Sponsored ADR (CMMB) could be a good stock pick from a technical perspective.
Chemomab Therapeutics Announces First Quarter 2024 Financial Results and Provides Corporate Update
07:00am, Thursday, 09'th May 2024
─On Track for Midyear 2024 Topline Data and Late 2024/Early 2025 Open Label Data Readouts from CM-101 Phase 2 Trial in Primary Sclerosing Cholangitis (PSC), Following Early Completion of Patient En
Chemomab Therapeutics Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Price Rule
07:00am, Wednesday, 08'th May 2024
TEL AVIV, Israel, May 08, 2024 (GLOBE NEWSWIRE) -- Chemomab Therapeutics Ltd. (Nasdaq: CMMB) (Chemomab), a clinical stage biotechnology company developing innovative therapeutics for fibro-inflammator
Chemomab Therapeutics to Present at 2024 Aegis Virtual Conference
07:00am, Thursday, 02'nd May 2024
TEL AVIV, Israel, May 02, 2024 (GLOBE NEWSWIRE) -- Chemomab Therapeutics Ltd. (Nasdaq: CMMB) (Chemomab), a clinical stage biotechnology company developing innovative therapeutics for fibro-inflammator
Chemomab Therapeutics to Report First Quarter 2024 Financial Results and Provide a Business Update
07:00am, Wednesday, 24'th Apr 2024
TEL AVIV, Israel, April 24, 2024 (GLOBE NEWSWIRE) -- Chemomab Therapeutics Ltd. (Nasdaq: CMMB), (Chemomab), a clinical stage biotechnology company developing innovative therapeutics for fibro-inflamma
Peer-reviewed patient study validates Chemomab's CCL24 as a novel target linked to greater disease severity and higher mortality in systemic sclerosis
Chemomab to Host Virtual Key Opinion Leader Webinar on Primary Sclerosing Cholangitis on April 10, 2024
07:00am, Tuesday, 02'nd Apr 2024
Chemomab's KOL primary sclerosing cholangitis virtual event on April 10 at 10:00 AM ET will include physician & patient PSC experts & a live Q&A session.
